Anti-inflammatory Dietary Intervention in Patients With Type 2 Diabetes: A Randomized Controlled Trial

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAnhui Medical University

About this trial

The goal of this clinical trial is to evaluate whether an evidence-based anti-inflammatory dietary intervention can reduce inflammation and improve glycemic control in patients with type 2 diabetes mellitus (T2DM). T2DM is a chronic metabolic disease characterized by elevated blood glucose levels and is closely associated with chronic low-grade inflammation.

The main questions it aims to answer are:

Does an anti-inflammatory dietary intervention reduce levels of hs-CRP, a key marker of chronic inflammation, in patients with T2DM? Does the intervention improve dietary inflammatory index (DII) scores and glycemic outcomes, including fasting blood glucose and 2-hour postprandial blood glucose? Researchers will compare an anti-inflammatory diet intervention group to a standard diabetes dietary control group to determine whether the anti-inflammatory dietary pattern provides additional benefits beyond routine dietary management.

Participants will:

Be randomly assigned to either the anti-inflammatory diet group or the standard diabetes diet group Receive dietary guidance based on structured anti-inflammatory food recommendations or routine diabetes dietary advice Complete dietary assessments, including 24-hour dietary recalls to calculate dietary inflammatory index (DII) Provide blood samples to measure hs-CRP, fasting blood glucose, and 2-hour postprandial blood glucose at baseline and after 4 weeks Complete questionnaires on dietary adherence and quality of life Participate in a 4-week intervention period with follow-up assessments

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients who meet the diagnostic criteria for type 2 diabetes mellitus (T2DM) according to the Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus in China (2020 Edition);

Aged 18 years or older;

Able and willing to complete all study questionnaires;

Willing to provide blood samples for laboratory testing;

Disqualifiers

Patients with a history of diseases affecting blood glucose metabolism, such as hyperthyroidism or Cushing's syndrome;

Pregnant or breastfeeding women;

Patients with severe hepatic dysfunction, renal dysfunction, heart failure, or malignant tumors;

Patients with acute or chronic infectious diseases accompanied by obvious signs of infection, including clinically diagnosed intestinal infections, respiratory tract infections, periodontitis, and other infectious conditions;

Trial design

Design model

Parallel

Treatments tested in this trial

  • Anti-inflammatory Dietary Intervention

    Behavioral

    Participants in this group will receive a 4-week evidence-based anti-inflammatory dietary intervention in addition to routine diabetes care.

  • Standard Diabetes Dietary Advice

    Behavioral

    Participants will receive routine dietary guidance for diabetes management according to standard clinical dietary recommendations for 4 weeks.

Treatment groups

88 Participants
are divided into 2 treatment groups
Group A: Anti-inflammatory Diet Intervention GroupExperimental treatment 1 intervention
Group B: Standard Diabetes Diet Control GroupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

high-sensitivity C-reactive protein (hs-CRP)

Time frame
Week 4

Secondary outcomes

1

Fasting Blood Glucose (FBG)

Time frame
Week 4
2

2-hour Postprandial Blood Glucose (2hPBG)

Time frame
Week 4
3

Dietary Inflammatory Index (DII)

Time frame
Week 4
4

Dietary Adherence Score in Patients with Type 2 Diabetes Mellitus

Time frame
Week 4

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.